1
项与 UD TGFbetai NK Cells(Ohio State University Comprehensive Cancer Center) 相关的临床试验A Phase I/II Study of Ex-Vivo Expanded Allogeneic Universal Donor (UD) TGFbi NK Cell Infusions in Combination With Temozolomide as a Lymphodepleting Agent in Patients With Melanoma Metastatic to the Brain
This phase I/II trial tests the safety, side effects, and best dose of universal donor UD TGFbetai natural killer (NK) cells, and whether UD TGFbetai NK cells with temozolomide works to shrink tumors in patients with stage IV melanoma that has spread to the brain (metastatic to the brain). NK cells are immune cells that contribute to anti-tumor immunity by recognizing and destroying transformed or stressed cells. Temozolomide is in a class of medications called alkylating agents. It works by slowing or stopping the growth of cancer cells in the body. Giving UD TGFbetai NK cell and temozolomide may work better in treating patients with stage IV melanoma.
100 项与 UD TGFbetai NK Cells(Ohio State University Comprehensive Cancer Center) 相关的临床结果
100 项与 UD TGFbetai NK Cells(Ohio State University Comprehensive Cancer Center) 相关的转化医学
100 项与 UD TGFbetai NK Cells(Ohio State University Comprehensive Cancer Center) 相关的专利(医药)
100 项与 UD TGFbetai NK Cells(Ohio State University Comprehensive Cancer Center) 相关的药物交易